Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature

International Journal of Cancer(2022)10.1002/ijc.33969Source: DataRank Database

Clinical and molecular characteristics of estrogen receptor‐positive ultralow risk breast cancer tumors identified by the 70‐gene signature is a research paper published in International Journal of Cancer (2022). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 1.77)OA: hybridTopics (59)IDs (PubMed, PMC, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (13)

Nancy Yu ORCID,Adina Iftimi ORCID,Nicholas P. Tobin ORCID,Laura van 't Veer,Bo Nordenskjöld ORCID

Live enrichment

PubMed:35179782 PMC:PMC9083187 OpenAlex:https://openalex.org/W4213098392

California Breast Cancer Research Program

Grant: 180B‐0065

Forskningsrådet om Hälsa, Arbetsliv och Välfärd

Grant: 2019‐00477

Cancerfonden

Grant: 180385

NCI NIH HHS

Grant: U01 CA196406

Cancerfonden

Grant: 190140

Vetenskapsrådet

Grant: 2020‐02466

National Institutes of Health

Grant: U01‐CA196406

Swedish Research Council for Health, Working Life and Welfare

Grant: unidentified

unidentified

National Institutes of Health

Grant: 5U01CA196406-04

Elucidating the molecular and contextual basis for IDLE ultralow risk lesions and the tumor immune microenvironment of high risk in situ and invasive breast cancers

Cancerföreningen i Stockholm

FWCI

1.77

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

hybridLicense: cc-by

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33969

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/ijc.33969

journalhttps://doi.org/10.1002/ijc.33969

repositoryhttps://pubmed.ncbi.nlm.nih.gov/35179782

repositoryhttp://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-183762

Fields of Study

Breast Cancer Treatment StudiesAdvanced Breast Cancer TherapiesCancer Genomics and Diagnostics03 medical and health sciences0302 clinical medicine

MeSH Terms

Breast NeoplasmsFemaleHumansReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorReceptor, ErbB-2Erb-b2 Receptor Tyrosine KinasesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Keywords

Breast cancerEstrogen receptorOncologyEstrogenCancer researchInternal medicineGeneMedicineBiologyCancerGeneticsPrognosisGene ExpressionLong-term Survival70-Gene SignatureUltralow Risk70-gene signature; breast cancer; gene expression; long-term survival; prognosis; ultralow riskTumor Markers and SignaturesOncology and CarcinogenesiscàncerBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesPhosphatidylinositol 3-KinasesErbB-2Clinical ResearchReceptorsBiomarkers, TumorHumansOncology & CarcinogenesisProgesteronescreening and diagnosisCancer och onkologiTumorTOR Serine-Threonine KinasesDetectionReceptors, EstrogenCancer and OncologyFemaleReceptors, ProgesteroneProto-Oncogene Proteins c-aktBiomarkers4.2 Evaluation of markers and technologiesReceptor

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being